Ablynx gains on RA data for vobarilizumab

Ablynx N.V. (Euronext:ABLX) gained EUR 1.42 (12%) to EUR 12.95 on Thursday after reporting 12-week data from a 251-patient Phase IIb study comparing three dosing regimens of vobarilizumab (ALX-0061) to more frequently dosed Actemra tocilizumab to treat moderately

Read the full 385 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE